Cardio-renal effect of dapagliflozin and dapagliflozin- saxagliptin combination on CD34 + ve hematopoietic stem cells (HSCs) and podocyte specific markers in type 2 diabetes (T2DM) subjects: a randomized trial
Introduction Effects of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) was examined on peripheral blood derived CD34 + Hematopoetic Stem Cells (HSCs) as a cellular CVD biomarker. Both Dapa (a sodium-glucose co-transporter 2 or SGLT2, receptor inhibitor) and Saxagliptin (a Di-...
Saved in:
| Published in | Stem cell research & therapy Vol. 16; no. 1; pp. 28 - 18 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
26.01.2025
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1757-6512 1757-6512 |
| DOI | 10.1186/s13287-025-04130-x |
Cover
| Abstract | Introduction
Effects of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) was examined on peripheral blood derived CD34 + Hematopoetic Stem Cells (HSCs) as a cellular CVD biomarker. Both Dapa (a sodium-glucose co-transporter 2 or SGLT2, receptor inhibitor) and Saxagliptin (a Di-peptydl-peptidase-4 or DPP4 enzyme inhibitor) are commonly used type 2 diabetes mellitus or T2DM medications, however the benefit of using the combination has not been evaluated for cardio-renal risk assessment, in a real-life practice setting, compared to a placebo.
Hypothesis
We hypothesized that Dapa will improve the outcomes when compared to placebo and the Combo maybe even more beneficial.
Methods
This is a pilot study evaluating low dose Dapagliflozin 10 mg or low dose Dapa + low dose Saxagliptin combination. 15 subjects were enrolled in 16 weeks, double-blind, three-arm, randomized placebo matched trial, with 10mg
Dapa
+ Saxa placebo (
n
= 4), 10 mg Dapa + 5 mg Saxa (
n
= 5)
Combo
, And Dapa placebo + Saxa placebo (
n
= 6),
Placebo
groups. T2DM subjects (age 30–70 yrs) with HbA1c of 7–10%, were included. CD34 + HSC number, migration, mRNA expression along with biochemistry and urine exosomes were measured. Data were collected at week 0, 8, and 16. For statistics, a mixed model regression analysis was used.
Results
Significant HbA1c (
p
= 0.0357) reduction was noted in Combo group versus Dapa alone and Placebo. hsCRP levels (
P
= 0.0317) and IL-6, two important inflammatory molecules, were significantly reduced in both Dapa and Combo vs. Placebo. Leptin levels decreased significantly in both Dapa alone (
p
= 0.035) and Combo group(
p
= 0.015), vs. Placebo, however the Adiponectin levels were higher in Dapa alone group. Dapagliflozin alone reduced lipid parameters significantly particularly triglyceride (TG) when compared to placebo, with resultant visit 3 values at 99.5
±
7.2 vs. 129
±
12.3 and LDL/HDL ratio values were similar at 2.18
±
0.08 vs. 2.13
±
0.15. CD34 + cell migration improved significantly in both Dapa alone (
p
= 0.05) and Combo group (
p
= 0.05) vs. Placebo.
Conclusions
Several parameters showed significant improvement with both Dapa alone and Combo compared to placebo. However, when all outcome measures were taken into account, other than glycemic control the Combo didn’t seem to offer any further benefit, over Dapa alone. Therefore, contrary to our initial hypothesis we do not believe the more expensive Dapa + Saxa combination offers any specific cardiovascular benefit compared to Dapagliflozin alone. However it is noteworthy that both Dapa and its combination with Saxagliptin showed significant improvement compared to placebo in T2DM, particularly when progenitor cell based numbers and function were analyzed and taken into account.
Trial Registration
The trial was registered with Clinical Trials.gov number NCT03660683, last updated 06052023. |
|---|---|
| AbstractList | Introduction
Effects of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) was examined on peripheral blood derived CD34 + Hematopoetic Stem Cells (HSCs) as a cellular CVD biomarker. Both Dapa (a sodium-glucose co-transporter 2 or SGLT2, receptor inhibitor) and Saxagliptin (a Di-peptydl-peptidase-4 or DPP4 enzyme inhibitor) are commonly used type 2 diabetes mellitus or T2DM medications, however the benefit of using the combination has not been evaluated for cardio-renal risk assessment, in a real-life practice setting, compared to a placebo.
Hypothesis
We hypothesized that Dapa will improve the outcomes when compared to placebo and the Combo maybe even more beneficial.
Methods
This is a pilot study evaluating low dose Dapagliflozin 10 mg or low dose Dapa + low dose Saxagliptin combination. 15 subjects were enrolled in 16 weeks, double-blind, three-arm, randomized placebo matched trial, with 10mg
Dapa
+ Saxa placebo (
n
= 4), 10 mg Dapa + 5 mg Saxa (
n
= 5)
Combo
, And Dapa placebo + Saxa placebo (
n
= 6),
Placebo
groups. T2DM subjects (age 30–70 yrs) with HbA1c of 7–10%, were included. CD34 + HSC number, migration, mRNA expression along with biochemistry and urine exosomes were measured. Data were collected at week 0, 8, and 16. For statistics, a mixed model regression analysis was used.
Results
Significant HbA1c (
p
= 0.0357) reduction was noted in Combo group versus Dapa alone and Placebo. hsCRP levels (
P
= 0.0317) and IL-6, two important inflammatory molecules, were significantly reduced in both Dapa and Combo vs. Placebo. Leptin levels decreased significantly in both Dapa alone (
p
= 0.035) and Combo group(
p
= 0.015), vs. Placebo, however the Adiponectin levels were higher in Dapa alone group. Dapagliflozin alone reduced lipid parameters significantly particularly triglyceride (TG) when compared to placebo, with resultant visit 3 values at 99.5
±
7.2 vs. 129
±
12.3 and LDL/HDL ratio values were similar at 2.18
±
0.08 vs. 2.13
±
0.15. CD34 + cell migration improved significantly in both Dapa alone (
p
= 0.05) and Combo group (
p
= 0.05) vs. Placebo.
Conclusions
Several parameters showed significant improvement with both Dapa alone and Combo compared to placebo. However, when all outcome measures were taken into account, other than glycemic control the Combo didn’t seem to offer any further benefit, over Dapa alone. Therefore, contrary to our initial hypothesis we do not believe the more expensive Dapa + Saxa combination offers any specific cardiovascular benefit compared to Dapagliflozin alone. However it is noteworthy that both Dapa and its combination with Saxagliptin showed significant improvement compared to placebo in T2DM, particularly when progenitor cell based numbers and function were analyzed and taken into account.
Trial Registration
The trial was registered with Clinical Trials.gov number NCT03660683, last updated 06052023. Abstract Introduction Effects of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) was examined on peripheral blood derived CD34 + Hematopoetic Stem Cells (HSCs) as a cellular CVD biomarker. Both Dapa (a sodium-glucose co-transporter 2 or SGLT2, receptor inhibitor) and Saxagliptin (a Di-peptydl-peptidase-4 or DPP4 enzyme inhibitor) are commonly used type 2 diabetes mellitus or T2DM medications, however the benefit of using the combination has not been evaluated for cardio-renal risk assessment, in a real-life practice setting, compared to a placebo. Hypothesis We hypothesized that Dapa will improve the outcomes when compared to placebo and the Combo maybe even more beneficial. Methods This is a pilot study evaluating low dose Dapagliflozin 10 mg or low dose Dapa + low dose Saxagliptin combination. 15 subjects were enrolled in 16 weeks, double-blind, three-arm, randomized placebo matched trial, with 10mg Dapa + Saxa placebo (n = 4), 10 mg Dapa + 5 mg Saxa (n = 5) Combo, And Dapa placebo + Saxa placebo (n = 6), Placebo groups. T2DM subjects (age 30–70 yrs) with HbA1c of 7–10%, were included. CD34 + HSC number, migration, mRNA expression along with biochemistry and urine exosomes were measured. Data were collected at week 0, 8, and 16. For statistics, a mixed model regression analysis was used. Results Significant HbA1c (p = 0.0357) reduction was noted in Combo group versus Dapa alone and Placebo. hsCRP levels (P = 0.0317) and IL-6, two important inflammatory molecules, were significantly reduced in both Dapa and Combo vs. Placebo. Leptin levels decreased significantly in both Dapa alone (p = 0.035) and Combo group(p = 0.015), vs. Placebo, however the Adiponectin levels were higher in Dapa alone group. Dapagliflozin alone reduced lipid parameters significantly particularly triglyceride (TG) when compared to placebo, with resultant visit 3 values at 99.5 ± 7.2 vs. 129 ± 12.3 and LDL/HDL ratio values were similar at 2.18 ± 0.08 vs. 2.13 ± 0.15. CD34 + cell migration improved significantly in both Dapa alone (p = 0.05) and Combo group (p = 0.05) vs. Placebo. Conclusions Several parameters showed significant improvement with both Dapa alone and Combo compared to placebo. However, when all outcome measures were taken into account, other than glycemic control the Combo didn’t seem to offer any further benefit, over Dapa alone. Therefore, contrary to our initial hypothesis we do not believe the more expensive Dapa + Saxa combination offers any specific cardiovascular benefit compared to Dapagliflozin alone. However it is noteworthy that both Dapa and its combination with Saxagliptin showed significant improvement compared to placebo in T2DM, particularly when progenitor cell based numbers and function were analyzed and taken into account. Trial Registration The trial was registered with Clinical Trials.gov number NCT03660683, last updated 06052023. Effects of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) was examined on peripheral blood derived CD34 + Hematopoetic Stem Cells (HSCs) as a cellular CVD biomarker. Both Dapa (a sodium-glucose co-transporter 2 or SGLT2, receptor inhibitor) and Saxagliptin (a Di-peptydl-peptidase-4 or DPP4 enzyme inhibitor) are commonly used type 2 diabetes mellitus or T2DM medications, however the benefit of using the combination has not been evaluated for cardio-renal risk assessment, in a real-life practice setting, compared to a placebo. We hypothesized that Dapa will improve the outcomes when compared to placebo and the Combo maybe even more beneficial. This is a pilot study evaluating low dose Dapagliflozin 10 mg or low dose Dapa + low dose Saxagliptin combination. 15 subjects were enrolled in 16 weeks, double-blind, three-arm, randomized placebo matched trial, with 10mg Dapa + Saxa placebo (n = 4), 10 mg Dapa + 5 mg Saxa (n = 5) Combo, And Dapa placebo + Saxa placebo (n = 6), Placebo groups. T2DM subjects (age 30-70 yrs) with HbA1c of 7-10%, were included. CD34 + HSC number, migration, mRNA expression along with biochemistry and urine exosomes were measured. Data were collected at week 0, 8, and 16. For statistics, a mixed model regression analysis was used. Significant HbA1c (p = 0.0357) reduction was noted in Combo group versus Dapa alone and Placebo. hsCRP levels (P = 0.0317) and IL-6, two important inflammatory molecules, were significantly reduced in both Dapa and Combo vs. Placebo. Leptin levels decreased significantly in both Dapa alone (p = 0.035) and Combo group(p = 0.015), vs. Placebo, however the Adiponectin levels were higher in Dapa alone group. Dapagliflozin alone reduced lipid parameters significantly particularly triglyceride (TG) when compared to placebo, with resultant visit 3 values at 99.5 ± 7.2 vs. 129 ± 12.3 and LDL/HDL ratio values were similar at 2.18 ± 0.08 vs. 2.13 ± 0.15. CD34 + cell migration improved significantly in both Dapa alone (p = 0.05) and Combo group (p = 0.05) vs. Placebo. Several parameters showed significant improvement with both Dapa alone and Combo compared to placebo. However, when all outcome measures were taken into account, other than glycemic control the Combo didn't seem to offer any further benefit, over Dapa alone. Therefore, contrary to our initial hypothesis we do not believe the more expensive Dapa + Saxa combination offers any specific cardiovascular benefit compared to Dapagliflozin alone. However it is noteworthy that both Dapa and its combination with Saxagliptin showed significant improvement compared to placebo in T2DM, particularly when progenitor cell based numbers and function were analyzed and taken into account. The trial was registered with Clinical Trials.gov number NCT03660683, last updated 06052023. Introduction Effects of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) was examined on peripheral blood derived CD34 + Hematopoetic Stem Cells (HSCs) as a cellular CVD biomarker. Both Dapa (a sodium-glucose co-transporter 2 or SGLT2, receptor inhibitor) and Saxagliptin (a Di-peptydl-peptidase-4 or DPP4 enzyme inhibitor) are commonly used type 2 diabetes mellitus or T2DM medications, however the benefit of using the combination has not been evaluated for cardio-renal risk assessment, in a real-life practice setting, compared to a placebo. Hypothesis We hypothesized that Dapa will improve the outcomes when compared to placebo and the Combo maybe even more beneficial. Methods This is a pilot study evaluating low dose Dapagliflozin 10 mg or low dose Dapa + low dose Saxagliptin combination. 15 subjects were enrolled in 16 weeks, double-blind, three-arm, randomized placebo matched trial, with 10mg Dapa + Saxa placebo (n = 4), 10 mg Dapa + 5 mg Saxa (n = 5) Combo, And Dapa placebo + Saxa placebo (n = 6), Placebo groups. T2DM subjects (age 30-70 yrs) with HbA1c of 7-10%, were included. CD34 + HSC number, migration, mRNA expression along with biochemistry and urine exosomes were measured. Data were collected at week 0, 8, and 16. For statistics, a mixed model regression analysis was used. Results Significant HbA1c (p = 0.0357) reduction was noted in Combo group versus Dapa alone and Placebo. hsCRP levels (P = 0.0317) and IL-6, two important inflammatory molecules, were significantly reduced in both Dapa and Combo vs. Placebo. Leptin levels decreased significantly in both Dapa alone (p = 0.035) and Combo group(p = 0.015), vs. Placebo, however the Adiponectin levels were higher in Dapa alone group. Dapagliflozin alone reduced lipid parameters significantly particularly triglyceride (TG) when compared to placebo, with resultant visit 3 values at 99.5 ± 7.2 vs. 129 ± 12.3 and LDL/HDL ratio values were similar at 2.18 ± 0.08 vs. 2.13 ± 0.15. CD34 + cell migration improved significantly in both Dapa alone (p = 0.05) and Combo group (p = 0.05) vs. Placebo. Conclusions Several parameters showed significant improvement with both Dapa alone and Combo compared to placebo. However, when all outcome measures were taken into account, other than glycemic control the Combo didn't seem to offer any further benefit, over Dapa alone. Therefore, contrary to our initial hypothesis we do not believe the more expensive Dapa + Saxa combination offers any specific cardiovascular benefit compared to Dapagliflozin alone. However it is noteworthy that both Dapa and its combination with Saxagliptin showed significant improvement compared to placebo in T2DM, particularly when progenitor cell based numbers and function were analyzed and taken into account. Trial Registration The trial was registered with Clinical Trials.gov number NCT03660683, last updated 06052023. Effects of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) was examined on peripheral blood derived CD34 + Hematopoetic Stem Cells (HSCs) as a cellular CVD biomarker. Both Dapa (a sodium-glucose co-transporter 2 or SGLT2, receptor inhibitor) and Saxagliptin (a Di-peptydl-peptidase-4 or DPP4 enzyme inhibitor) are commonly used type 2 diabetes mellitus or T2DM medications, however the benefit of using the combination has not been evaluated for cardio-renal risk assessment, in a real-life practice setting, compared to a placebo.INTRODUCTIONEffects of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) was examined on peripheral blood derived CD34 + Hematopoetic Stem Cells (HSCs) as a cellular CVD biomarker. Both Dapa (a sodium-glucose co-transporter 2 or SGLT2, receptor inhibitor) and Saxagliptin (a Di-peptydl-peptidase-4 or DPP4 enzyme inhibitor) are commonly used type 2 diabetes mellitus or T2DM medications, however the benefit of using the combination has not been evaluated for cardio-renal risk assessment, in a real-life practice setting, compared to a placebo.We hypothesized that Dapa will improve the outcomes when compared to placebo and the Combo maybe even more beneficial.HYPOTHESISWe hypothesized that Dapa will improve the outcomes when compared to placebo and the Combo maybe even more beneficial.This is a pilot study evaluating low dose Dapagliflozin 10 mg or low dose Dapa + low dose Saxagliptin combination. 15 subjects were enrolled in 16 weeks, double-blind, three-arm, randomized placebo matched trial, with 10mg Dapa + Saxa placebo (n = 4), 10 mg Dapa + 5 mg Saxa (n = 5) Combo, And Dapa placebo + Saxa placebo (n = 6), Placebo groups. T2DM subjects (age 30-70 yrs) with HbA1c of 7-10%, were included. CD34 + HSC number, migration, mRNA expression along with biochemistry and urine exosomes were measured. Data were collected at week 0, 8, and 16. For statistics, a mixed model regression analysis was used.METHODSThis is a pilot study evaluating low dose Dapagliflozin 10 mg or low dose Dapa + low dose Saxagliptin combination. 15 subjects were enrolled in 16 weeks, double-blind, three-arm, randomized placebo matched trial, with 10mg Dapa + Saxa placebo (n = 4), 10 mg Dapa + 5 mg Saxa (n = 5) Combo, And Dapa placebo + Saxa placebo (n = 6), Placebo groups. T2DM subjects (age 30-70 yrs) with HbA1c of 7-10%, were included. CD34 + HSC number, migration, mRNA expression along with biochemistry and urine exosomes were measured. Data were collected at week 0, 8, and 16. For statistics, a mixed model regression analysis was used.Significant HbA1c (p = 0.0357) reduction was noted in Combo group versus Dapa alone and Placebo. hsCRP levels (P = 0.0317) and IL-6, two important inflammatory molecules, were significantly reduced in both Dapa and Combo vs. Placebo. Leptin levels decreased significantly in both Dapa alone (p = 0.035) and Combo group(p = 0.015), vs. Placebo, however the Adiponectin levels were higher in Dapa alone group. Dapagliflozin alone reduced lipid parameters significantly particularly triglyceride (TG) when compared to placebo, with resultant visit 3 values at 99.5 ± 7.2 vs. 129 ± 12.3 and LDL/HDL ratio values were similar at 2.18 ± 0.08 vs. 2.13 ± 0.15. CD34 + cell migration improved significantly in both Dapa alone (p = 0.05) and Combo group (p = 0.05) vs. Placebo.RESULTSSignificant HbA1c (p = 0.0357) reduction was noted in Combo group versus Dapa alone and Placebo. hsCRP levels (P = 0.0317) and IL-6, two important inflammatory molecules, were significantly reduced in both Dapa and Combo vs. Placebo. Leptin levels decreased significantly in both Dapa alone (p = 0.035) and Combo group(p = 0.015), vs. Placebo, however the Adiponectin levels were higher in Dapa alone group. Dapagliflozin alone reduced lipid parameters significantly particularly triglyceride (TG) when compared to placebo, with resultant visit 3 values at 99.5 ± 7.2 vs. 129 ± 12.3 and LDL/HDL ratio values were similar at 2.18 ± 0.08 vs. 2.13 ± 0.15. CD34 + cell migration improved significantly in both Dapa alone (p = 0.05) and Combo group (p = 0.05) vs. Placebo.Several parameters showed significant improvement with both Dapa alone and Combo compared to placebo. However, when all outcome measures were taken into account, other than glycemic control the Combo didn't seem to offer any further benefit, over Dapa alone. Therefore, contrary to our initial hypothesis we do not believe the more expensive Dapa + Saxa combination offers any specific cardiovascular benefit compared to Dapagliflozin alone. However it is noteworthy that both Dapa and its combination with Saxagliptin showed significant improvement compared to placebo in T2DM, particularly when progenitor cell based numbers and function were analyzed and taken into account.CONCLUSIONSSeveral parameters showed significant improvement with both Dapa alone and Combo compared to placebo. However, when all outcome measures were taken into account, other than glycemic control the Combo didn't seem to offer any further benefit, over Dapa alone. Therefore, contrary to our initial hypothesis we do not believe the more expensive Dapa + Saxa combination offers any specific cardiovascular benefit compared to Dapagliflozin alone. However it is noteworthy that both Dapa and its combination with Saxagliptin showed significant improvement compared to placebo in T2DM, particularly when progenitor cell based numbers and function were analyzed and taken into account.The trial was registered with Clinical Trials.gov number NCT03660683, last updated 06052023.TRIAL REGISTRATIONThe trial was registered with Clinical Trials.gov number NCT03660683, last updated 06052023. |
| ArticleNumber | 28 |
| Audience | Academic |
| Author | Sen, Sabyasachi Nandula, Seshagiri Rao Jain, Arad |
| Author_xml | – sequence: 1 givenname: Seshagiri Rao surname: Nandula fullname: Nandula, Seshagiri Rao organization: Department of Medicine, Veterans Affairs Medical Center, Department of Medicine, George Washington University, Department of Biochemistry, George Washington University – sequence: 2 givenname: Arad surname: Jain fullname: Jain, Arad organization: Department of Medicine, Veterans Affairs Medical Center, Department of Medicine, George Washington University, Department of Biochemistry, George Washington University – sequence: 3 givenname: Sabyasachi orcidid: 0000-0002-3675-9129 surname: Sen fullname: Sen, Sabyasachi email: ssen1@gwu.edu organization: Department of Medicine, Veterans Affairs Medical Center, Department of Medicine, George Washington University, Department of Biochemistry, George Washington University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39865301$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAUhSNUREvpC7BAXqFWKOC__JgNqqZAKxWxoKwtx76Z8ZDEqe1UM12x5QF5AZ4Ez0yp2g1WLCe-5346ds7zbG9wA2TZS4LfElKX7wJhtK5yTIscc8JwvnqSHZCqqPKyIHTvwft-dhTCEqfBGMYlf5btM1GXBcPkIPs9U95Yl3sYVIegbUFH5Fpk1KjmnW07d2sHpAbzeCdHQa02n2NMZe36xg4qWjeg9MzOGP_z89ebNG8ALaBX0Y3OQrQahQg90tB1AR2ff5uFky17dMbpdQQURtC2Tbpe-R_gA0r0uB4BUWSsaiBC6ruiZ19OUJiaZTIb3iOFfIK43t6CQdFb1b3InraqC3B0tx5m3z99vJqd55dfP1_MTi9zzUUR88aUXGhRFJXCtDTQCoy5YbikLTGiZoCpEJjrusJcCaGrptas0IrxiutC1-wwu9hxjVNLOXqbbK-lU1ZuN5yfS-XTsTuQVGBhGDBCyoJTympdEU0rCglYNg1OrA871jg1PRgNQ_SqewR9XBnsQs7djSSkqrCgVSIc3xG8u54gRNnbsLlrNYCbgmSkxDgdpSyT9PVOOlfJ2wJUFxfBddPmFwZ5WtN0P3XBN8JXD13d2_mXoCSgO4H2LgQP7b2EYLlJqtwlVaakym1S5So1sV1TSOJhDl4u3eRTAsP_uv4CRN3uUQ |
| Cites_doi | 10.14740/jem273w 10.1089/met.2018.0121 10.1038/ncpendmet0366 10.1161/CIRCULATIONAHA.106.687376 10.1089/met.2022.0004 10.2337/dc14-1142 10.1172/JCI36858 10.1016/S2213-8587(19)30086-5 10.3390/nu13082493 10.1186/s12933-020-01046-z 10.1161/JAHA.116.005146 10.1161/CIRCRESAHA.111.245993 10.1111/dom.13437 10.1186/s12933-021-01235-4 10.1186/s12933-018-0709-9 10.1016/j.diabres.2019.107843 10.2337/dc10-0187 10.1089/met.2016.0136 10.1056/NEJMoa022287 10.1056/NEJMoa043814 10.1111/j.1476-5381.2012.02102.x |
| ContentType | Journal Article |
| Copyright | This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025 2025. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply. COPYRIGHT 2025 BioMed Central Ltd. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025 2025 |
| Copyright_xml | – notice: This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025 – notice: 2025. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply. – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025 2025 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1186/s13287-025-04130-x |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1757-6512 |
| EndPage | 18 |
| ExternalDocumentID | oai_doaj_org_article_2909d3e3116542238c71c272e35c6bb0 PMC11770927 A824958546 39865301 10_1186_s13287_025_04130_x |
| Genre | Randomized Controlled Trial Journal Article |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: AstraZeneca United States grantid: AstraZeneca United States funderid: http://dx.doi.org/10.13039/100021316 – fundername: AstraZeneca United States grantid: AstraZeneca United States |
| GroupedDBID | --- 0R~ 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFS ACIHN ACJQM ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU DIK E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IEA IHR IHW INH INR ISR ITC KQ8 LK8 M1P M7P M~E O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO RBZ ROL RPM RSV SBL SOJ SV3 TUS UKHRP AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c495t-bd649c9557a026def9004d3062f1d983e029904c8704a99c7b8c35ca3474c5c83 |
| IEDL.DBID | DOA |
| ISSN | 1757-6512 |
| IngestDate | Wed Aug 27 01:27:30 EDT 2025 Thu Aug 21 18:40:38 EDT 2025 Thu Sep 04 23:44:56 EDT 2025 Thu May 22 21:23:43 EDT 2025 Mon Jul 21 05:30:40 EDT 2025 Tue Jul 01 02:42:31 EDT 2025 Sat Sep 06 07:28:33 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2025. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c495t-bd649c9557a026def9004d3062f1d983e029904c8704a99c7b8c35ca3474c5c83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-3675-9129 |
| OpenAccessLink | https://doaj.org/article/2909d3e3116542238c71c272e35c6bb0 |
| PMID | 39865301 |
| PQID | 3160070466 |
| PQPubID | 23479 |
| PageCount | 18 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_2909d3e3116542238c71c272e35c6bb0 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11770927 proquest_miscellaneous_3160070466 gale_healthsolutions_A824958546 pubmed_primary_39865301 crossref_primary_10_1186_s13287_025_04130_x springer_journals_10_1186_s13287_025_04130_x |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2025-01-26 |
| PublicationDateYYYYMMDD | 2025-01-26 |
| PublicationDate_xml | – month: 01 year: 2025 text: 2025-01-26 day: 26 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Stem cell research & therapy |
| PublicationTitleAbbrev | Stem Cell Res Ther |
| PublicationTitleAlternate | Stem Cell Res Ther |
| PublicationYear | 2025 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | DW Losordo (4130_CR8) 2011; 109 P Saeedi (4130_CR2) 2019; 157 GP Fadini (4130_CR4) 2010; 33 CY Huang (4130_CR5) 2012; 167 J Rosenstock (4130_CR15) 2015; 38 R Premji (4130_CR14) 2022; 20 C Pollock (4130_CR17) 2019; 7 DW Losordo (4130_CR6) 2007; 115 EJ Marrotte (4130_CR7) 2010; 120 HB Awal (4130_CR10) 2020; 19 D Müller-Wieland (4130_CR16) 2018; 20 4130_CR20 4130_CR11 4130_CR22 4130_CR13 CJ Holmes (4130_CR21) 2021; 13 4130_CR1 4130_CR18 4130_CR19 C Rask-Madsen (4130_CR3) 2007; 3 SR Nandula (4130_CR9) 2021; 20 S Sabyasachi Sen (4130_CR12) 2015; 5 |
| References_xml | – volume: 5 start-page: 163 issue: 1–2 year: 2015 ident: 4130_CR12 publication-title: J Endocrinol Metab doi: 10.14740/jem273w – ident: 4130_CR22 doi: 10.1089/met.2018.0121 – volume: 3 start-page: 46 issue: 1 year: 2007 ident: 4130_CR3 publication-title: Nat Clin Pract Endocrinol Metab doi: 10.1038/ncpendmet0366 – volume: 115 start-page: 3165 issue: 25 year: 2007 ident: 4130_CR6 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.106.687376 – volume: 20 start-page: 321 issue: 6 year: 2022 ident: 4130_CR14 publication-title: Metab Syndr Relat Disord doi: 10.1089/met.2022.0004 – volume: 38 start-page: 376 issue: 3 year: 2015 ident: 4130_CR15 publication-title: Diabetes Care doi: 10.2337/dc14-1142 – volume: 120 start-page: 4207 issue: 12 year: 2010 ident: 4130_CR7 publication-title: J Clin Invest doi: 10.1172/JCI36858 – volume: 7 start-page: 429 issue: 6 year: 2019 ident: 4130_CR17 publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(19)30086-5 – volume: 13 start-page: 2493 issue: 8 year: 2021 ident: 4130_CR21 publication-title: Nutrients doi: 10.3390/nu13082493 – volume: 19 start-page: 72 issue: 1 year: 2020 ident: 4130_CR10 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-020-01046-z – ident: 4130_CR13 doi: 10.1161/JAHA.116.005146 – ident: 4130_CR1 – volume: 109 start-page: 428 issue: 4 year: 2011 ident: 4130_CR8 publication-title: Circ Res doi: 10.1161/CIRCRESAHA.111.245993 – volume: 20 start-page: 2598 issue: 11 year: 2018 ident: 4130_CR16 publication-title: Diabetes Obes Metab doi: 10.1111/dom.13437 – volume: 20 start-page: 44 issue: 1 year: 2021 ident: 4130_CR9 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-021-01235-4 – ident: 4130_CR11 doi: 10.1186/s12933-018-0709-9 – volume: 157 start-page: 107843 year: 2019 ident: 4130_CR2 publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2019.107843 – volume: 33 start-page: 1607 issue: 7 year: 2010 ident: 4130_CR4 publication-title: Diabetes Care doi: 10.2337/dc10-0187 – ident: 4130_CR20 doi: 10.1089/met.2016.0136 – ident: 4130_CR18 doi: 10.1056/NEJMoa022287 – ident: 4130_CR19 doi: 10.1056/NEJMoa043814 – volume: 167 start-page: 1506 issue: 7 year: 2012 ident: 4130_CR5 publication-title: Br J Pharmacol doi: 10.1111/j.1476-5381.2012.02102.x |
| SSID | ssj0000330064 |
| Score | 2.3816025 |
| Snippet | Introduction
Effects of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) was examined on peripheral blood derived CD34 + Hematopoetic... Effects of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) was examined on peripheral blood derived CD34 + Hematopoetic Stem Cells... Introduction Effects of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) was examined on peripheral blood derived CD34 + Hematopoetic... Abstract Introduction Effects of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) was examined on peripheral blood derived CD34 +... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 28 |
| SubjectTerms | Adamantane - administration & dosage Adamantane - analogs & derivatives Adamantane - pharmacology Adamantane - therapeutic use Adult Aged Antigens, CD34 - metabolism Benzhydryl Compounds - administration & dosage Benzhydryl Compounds - pharmacology Benzhydryl Compounds - therapeutic use Biomarkers - metabolism Biomedical and Life Sciences Biomedical Engineering and Bioengineering Cell Biology Clinical trials Comparative analysis Dextrose Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Diabetes Mellitus, Type 2 - pathology Dipeptides - administration & dosage Dipeptides - pharmacology Dipeptides - therapeutic use Dipeptidyl-Peptidase IV Inhibitors Double-Blind Method Enzyme inhibitors Enzymes Female Glucose Glucosides - administration & dosage Glucosides - pharmacology Glucosides - therapeutic use Glycosylated hemoglobin Hematopoietic stem cells Hematopoietic Stem Cells - drug effects Hematopoietic Stem Cells - metabolism Humans Hypoglycemic agents Leptin Life Sciences Male Middle Aged Pilot Projects Regenerative Medicine/Tissue Engineering Risk assessment Stem Cells Type 2 diabetes |
| SummonAdditionalLinks | – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1baxNBFB6kIvgi3l2tegQfWuriXmZnZ3yrW0sQ6ost9G3YuWwNtLshm5S2T776A_0D_hLPmU1CU0UQspBsJrNDzm2-M-fC2FtkobRRQsUIFWzMjXWxaRQKXpo0PktKlVnKdz74IkZH_PNxcbwok0O5MNfP71Mp3veIllAMqOlqQvo2xv3i7QLfUPheJaqVPyVBYI7mdZkX89efrtmeUKL_T0V8zRLdjJK8cVQaLND-fXZvsXWE3YHWD9gt3z5kd4ZmkpeP2M8qhJbGU0-jhjgN6BpwaA5PTsfNaXc1bqFu3fqdGPr6gj6i7mgB-Q-hcqAW4Kvay_mv7z928Dr3EOq7dpNuTImPQBWggfz-PWyNvlb9dph7gjDXXs48UAonhSHBGQUATXvA2cnfCxks_b2wdZjtHWxDPzfkDeo_QA1oOl13Nr7yDkJDkcfsaP_TYTWKF00bYotYaxYbJ7iyqijKGuGd841CMXQITLImdUrmPiEDyC3qCV4rZUsjbV7YOuclt4WV-RO20Xatf8bACidwklq6xvCyKWuDZM-VyRvc0zjpI7azJKeeDLU5dMA0UuiB-BqJrwPx9UXEPhLFVyOprna4geymF2KqM5UoR35hSvLCp0hbpjYrM49LFMYkEXtN_KKHJNWVdtC7knp4y4KLiL1ZspJGSSUy1K3v5r3OU-oFkHCBY54OrLVaTK6kKFDXRkyuMd3aate_acffQjVwOnVPVFZG7N2SP_VCD_X_-Due_9_wF-xuFiQpjTOxyTZm07l_iduxmXkV5PA3fIgwfA priority: 102 providerName: Springer Nature |
| Title | Cardio-renal effect of dapagliflozin and dapagliflozin- saxagliptin combination on CD34 + ve hematopoietic stem cells (HSCs) and podocyte specific markers in type 2 diabetes (T2DM) subjects: a randomized trial |
| URI | https://link.springer.com/article/10.1186/s13287-025-04130-x https://www.ncbi.nlm.nih.gov/pubmed/39865301 https://www.proquest.com/docview/3160070466 https://pubmed.ncbi.nlm.nih.gov/PMC11770927 https://doaj.org/article/2909d3e3116542238c71c272e35c6bb0 |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: RBZ dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: KQ8 dateStart: 20100101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1757-6512 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: ABDBF dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: RPM dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: 7X7 dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1757-6512 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: BENPR dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Nature HAS Fully OA customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: AAJSJ dateStart: 20100301 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: C6C dateStart: 20100301 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF5BERIXxBtTCIvEoVWx6sd6H9xat1WE1ApBK-W2snfXJVJrR3FSpT1x5QfyB_glzKyTKCkSXJCSg53Vytn5Zsbf7jwIeQ8QiivFVQhUwYSsNDYsKwWKF0eVSyKhEoP5zscnvH_GPg2ywUqrL4wJ68oDdwu3m6hIWdypw7Qb8GXSiNgkInFpZnhZerYObmyFTHkbDDQdnO0iS0by3RZoF-gTdm-N0HCHszVP5Av2_2mWV_zS7ZjJWwen3h8dPSIP5y-SdK_7A4_JHVc_Ife71pLXT8nP3AeahmOHo7qoDdpU1IJzPL8YVhfNzbCmRW3X74S0LWZ4CZakpoBGIM5edhQ--UHKfn3_sQPfK0d9tddm1AwxDZJiPWiKpwAt3ep_zdttP_cISK-5njiKCZ0YlEQvMRxo3FKYHXd_aUIXu7906zQ5ON6m7bTEvaH2Iy0oOFLbXA5vnKW-vcgzcnZ0eJr3w3kLh9AA85qEpeVMGZVlogCyZ12lQCkt0JSkiq2SqYvQHTIDVoMVShlRSgOCLVImmMmMTJ-Tjbqp3UtCDbccJimkrUomKlGUgLNUlWkFqLDSBWRnIU496ip1aM9wJNed8DUIX3vh61lA9lHiy5FYZdvfAOzpOfb0v7AXkLeIF92lrC5thd6T2NFbZowH5N0CShr0FsVQ1K6ZtjqNsTNAxDiMedFBa_kwqZI8A8sbELkGurWnXf-lHn7ztcHxDD5SiQjIhwU-9dwqtX9Zjlf_Yzk2yYPE61ccJvw12ZiMp-4NvLJNyh65KwaiR-7tH558_gJXOc97XmN_A555QYc |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFLZQJwQvaNzDgBmJh00jWi6OY_NWOqZS1r2sk_ZmJbYzKm1J1bRo2xOv_ED-AL-Ec5ykogMhITUPTR3Xyrn5Oz4XQt4CC4WF5NIHqKB9lmvj54UEwQuDwkZBKiON-c7jYz48ZaOz5KxNCqu7aPfuSNJpaifWgu_XgJtAILD9aoCa14ed44ZIEs56ZKPfH52MVr6VAEA6mNouR-avD6_ZIVeu_0-l_JtVuh0xeevY1Fmjw03yoN1G0n5D94fkji0fkbtNY8nrx-THwIWZ-nOLo5qYDVoV1IBpPL-YFhfVzbSkWWnW7_i0zq7wK-iRksJrAdjsKEfhMziI2c9v3_fg-mqpq_VazaopJkFSrAZN8QygpjvDk0G96-aeAeTV1wtLMZ0TQ5LoJQYDzWsKs6Pvl0a08_3SnUl0MN6l9TJHz1D9nmYUzKipLqc31lDXXOQJOT38OBkM_baBg68Bdy383HAmtUySNAOoZ2whQSQNgJSoCI0UsQ3QGDINOoNlUuo0FzpOdBazlOlEi_gp6ZVVaZ8TqrnhMEkmTJGztEizHLgslnlcwP7GCOuRvY6catbU6VAO3wiuGuIrIL5yxFdXHvmAFF-NxBrb7kY1P1etyKpIBtKgjxgTvuBfhE5DHaWRhSXyPA88so38opqE1ZWmUH2B_bxFwrhH3nSspEBqkQxZaatlreIQ-wIEjMOYZw1rrRYTS8ET0LseEWtMt7ba9V_K6RdXGRxP4AMZpR551_GnanVS_Y_X8eL_hm-Te8PJ-EgdfTr-vEXuR06qQj_iL0lvMV_aV7BNW-SvW6n8BSFwON0 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFLbQJhAviPvCbUbiYdOIljiOY_NWWqpR2IS0TdqbldjOqLQlVdOibU-88gP5A_wSznGaah0ICal5aOq4Vs7N3_G5EPIGWCgulVAhQAUT8sLYsCgVCF4clY5FmWIG8533D8TeMR-dpCfXsvh9tHt3JNnmNGCVpmq2O7FlK-JS7DaAoUA4sBVrhFo4hF3kukyVAPi13uuNDkdLP0sEgB3Mbpcv89eHV2ySL93_p4K-ZqFuRk_eOEL1lml4n9xbbClpr-WBB-SWqx6S222TyctH5Gffh5yGU4ej2vgNWpfUgpk8PRuXZ_XVuKJ5ZVfvhLTJL_Ar6JSKwisCCO2pSOHTHyT81_cfO3B9c9TXfa0n9RgTIilWhqZ4HtDQrb3DfrPt554A_DWXM0cxtRPDk-g5BgZNGwqzox-YMtr5genWERvsb9NmXqCXqHlHcwom1dbn4ytnqW808pgcDz8c9ffCRTOH0AAGm4WFFVwZlaZZDrDPulKBeFoALKyMrZKJi9AwcgP6g-dKmayQJklNnvCMm9TI5AlZq-rKbRBqhBUwSS5tWfCszPICOC5RRVLCXsdKF5Cdjpx60tbs0B7rSKFb4msgvvbE1xcBeY8UX47Eetv-Rj091Qvx1UxFyqK_GJO_4F-kyWLDMuZgiaIoooBsIr_oNnl1qTV0T2Jvb5lyEZDXHStpkGAkQ165et7oJMYeAREXMOZpy1rLxSRKihR0cEDkCtOtrHb1l2r81VcJx9P4SLEsIG87_tQL_dT843U8-7_hm-TOl8FQf_548Ok5ucu8UMUhEy_I2mw6dy9hxzYrXi2E8jd4iz0n |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cardio-renal+effect+of+dapagliflozin+and+dapagliflozin-+saxagliptin+combination+on+CD34%E2%80%89%2B%E2%80%89ve+hematopoietic+stem+cells+%28HSCs%29+and+podocyte+specific+markers+in+type+2+diabetes+%28T2DM%29+subjects%3A+a+randomized+trial&rft.jtitle=Stem+cell+research+%26+therapy&rft.au=Nandula%2C+Seshagiri+Rao&rft.au=Jain%2C+Arad&rft.au=Sen%2C+Sabyasachi&rft.date=2025-01-26&rft.eissn=1757-6512&rft.volume=16&rft.issue=1&rft.spage=28&rft_id=info:doi/10.1186%2Fs13287-025-04130-x&rft_id=info%3Apmid%2F39865301&rft.externalDocID=39865301 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1757-6512&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1757-6512&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1757-6512&client=summon |